Second-generation (non-sedating) antihistamine — H1 antagonist
Pregnancy: Compatible — most safety data of second-generation antihistamines; preferred in pregnancy.
Loratadine 10mg Tablets
Brand names: Clarityn, Boots Allergy Relief
Adult dose
Dose: 10 mg once daily
Route: Oral
Frequency: Once daily
Max: 10 mg/day
Allergic rhinitis, urticaria, eczema: 10 mg once daily. Non-sedating at standard doses. May be taken with or without food. Available OTC. Duration of action 24 hours — once daily dosing adequate.
Paediatric dose
Route: Oral
Frequency: Once daily
Max: 10 mg/day
Concentration: 5 mg/ml
2–12 years <30 kg: 5 mg once daily (syrup 5mg/5mL). 2–12 years ≥30 kg: 10 mg once daily. ≥12 years: 10 mg once daily. Below age 2: not licensed.
Dose adjustments
Renal
eGFR <30: 10 mg on alternate days (increased half-life).
Hepatic
Severe hepatic impairment: 10 mg on alternate days.
Clinical pearls
- Preferred antihistamine in pregnancy — most human safety data of all second-generation antihistamines
- Non-sedating at therapeutic dose — safe for driving; some individuals may experience mild sedation
- Active metabolite desloratadine (Neoclarityn) available if preferred — slightly longer half-life
- Suitable for long-term use in perennial allergic rhinitis
- Available OTC — first-line recommendation for mild allergic rhinitis per ARIA guidelines
Contraindications
- Hypersensitivity to loratadine or desloratadine
Side effects
- Headache
- Dry mouth (mild)
- Fatigue
- Sedation (rare at standard dose; may occur in susceptible individuals)
- GI upset
Interactions
- Ketoconazole, erythromycin, cimetidine — increase loratadine plasma levels (limited clinical significance)
- CNS depressants — potential additive sedation at high doses
Monitoring
- Symptom response
Reference: BNFc; BNF; ARIA Guidelines; BSACI Allergic Rhinitis; BNFc. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Drugs
Pathways
- Adult Upper Airway Obstruction (Stridor) · DAS 2015 unanticipated difficult airway; RCEM
- Epistaxis Management · ENT-UK / NICE
- Acute Otitis Media · NICE NG91 2018
- Tonsillitis and Sore Throat · NICE NG84 2018
- Benign Paroxysmal Positional Vertigo · NICE CG124 / AAO-HNS Guidelines
- Acute Rhinosinusitis · NICE NG79 2017 / EPOS 2020